home / stock / kros / kros news

KROS News and Press, Keros Therapeutics Inc.

Stock Information
Company Name: Keros Therapeutics Inc.
Stock Symbol: KROS
Market: NASDAQ
Website: kerostx.com
Menu
Get KROS Alerts

News, Short Squeeze, Breakout and More Instantly...
KROS - Keros Therapeutics Appoints Anne Prener to its Board of Directors

LEXINGTON, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disord...
KROS - Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

2026-06-08 19:18:31 ET Keros Therapeutics, Inc. (KROS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 4:00 PM EDT... Read the full article on Seeking Alpha For further details see: Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annua...

KROS - Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference

LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunct...

KROS - Keros Therapeutics GAAP EPS of -$1.21 misses by $0.19, revenue of $0.37M misses by $1.32M

2026-05-14 08:03:16 ET More on Keros Therapeutics Seeking Alpha’s Quant Rating on Keros Therapeutics Historical earnings data for Keros Therapeutics Financial information for Keros Therapeutics Read the full article on Seeking Alpha For further...
KROS - Keros Therapeutics Reports Recent First Quarter 2026 Financial Results

LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorde...

KROS - Best Small Cap Value Stocks May 2026

2026-05-07 11:08:44 ET Don't forget about us! Many advisors and asset allocation models put a small cap slice into investor's portfolios ( VTWO ) by training and habit. The truth is, small caps have not provided a non-correlated hedging strategy to large cap indexes ( VOO )( I...

KROS - Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disor...
KROS - Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disor...

KROS - Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disor...

KROS - Expected US Company Earnings on Wednesday, March 4th, 2026

Riskified Ltd. Class A (RSKD) is expected to report $0.02 for Q4 2025 SunOpta Inc. (STKL) is expected to report $0.05 for Q4 2025 One Liberty Properties Inc. (OLP) is expected to report $0.41 for Q4 2025 Tourmaline Oil Corp (TRMLF) is expected to report $0.35 for Q4 2025 StubHub H...
Next 10